Exploring The Role Of MiRSNPs In Diagnosis And Prognosis Of Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$428,065.00
Summary
Genetic variants, when used alongside PSA and family history, could be a better early biomarker to identify men predisposable to develop prostate cancer or/and to distinguish slowly progressive from aggressive disease. We will undertake a comprehensive study on a special class of genetic variants "miRSNPs" in the non-coding region of the prostate cancer related genes and will also identify their mechanism of action, and their potential as a biomarker for prostate cancer diagnosis and prognosis.